You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure GPS-17. Last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34)

Country	Amphetamines	Ecstasy	Cocaine
Related links:
RO (2010)	0.0	0.4	0.2
EL (2004)	0.1	0.4	0.2
PL (2006)	1.3	0.7	0.3
LT (2008)	1.1	1.9	0.3
HU (2007)	1.2	1.0	0.4
CZ (2010)	0.8	1.6	0.5
NO (2009)	0.8	0.8	0.6
FI (2010)	1.6	1.1	0.6
LV (2007)	1.9	2.7	1.0
PT (2007)	0.4	0.9	1.2
AT (2008)	0.9	1.0	1.2
SE (2008)	1.5	0.2	1.2
EE (2008)	2.5	2.3	1.3
SK (2006)	0.7	2.7	1.3
BG (2008)	2.1	1.6	1.5
DE (2009)	1.9	1.0	1.8
FR (2010)	0.5	0.4	1.9
CY (2009)	0.7	1.0	2.2
NL (2009)		3.1	2.4
DK (2010)	2.0	0.8	2.5
IE (2010/11)	0.8	0.9	2.8
IT (2008)	0.6	1.0	2.9
UK (E&W) (2010/11)	2.0	3.0	4.2
ES (2009)	1.4	1.8	4.4
Statistical bulletin 2006: Figure GPS-23 part (i)
Statistical bulletin 2007: Figure GPS-17
Statistical bulletin 2008: Figure GPS-17
Statistical bulletin 2009: Figure GPS-17
Statistical bulletin 2010: Figure GPS-17
Statistical bulletin 2011: Figure GPS-17
See also Tables GPS-2 part ii and GPS-2 part iii
See also 'General notes for interpreting data' on the Explanatory notes and help page

Notes:

Sample sizes (n) refer to the number of respondents for 15- to 34-year-old group. For number of respondents for the whole surveys, see Epidemiological tables on population surveys in the Statistical bulletin 2012.

Data are from the most recent national surveys available in each country (see General population survey tables, Statistical bulletin 2012).

For young adults, the EMCDDA standard age range is 15 to 34 years (Denmark and the UK from 16 years, Estonia, Hungary and Germany from 18 years). Variations in age ranges may slightly influence some national differences. In some countries, the figures were recalculated at national level, to adapt as far as possible to standard EMCDDA age groups.

The most recent general population survey reported by the Netherlands display a wide variation in results compared with 2005 which may reflect methodological differences. The data is provided for information, but given the lack of comparability between surveys should be treated with caution.

Bulgaria: 2008; n=2164

Czech Republic: 2010; n=615

Denmark: 2010; n=3381

Germany: 2009; n=3876

Estonia: 2008; n=545

Ireland: 2010/11; n=n.a.

Greece: 2004; n=2620

Spain: 2009; n=n.a.

France: 2010; n=10855

Italy: 2008; n=6398

Cyprus: 2009; n=1810

Latvia: 2007; n =2497

Lithuania: 2008; n=2152

Hungary: 2007; n=1111

Netherlands: 2009; n=

Austria: 2008; n=2558

Poland: 2006; n=2031

Portugal: 2007; n=4765

Romania: 2010; n=3108

Slovakia: 2006; n=556

Finland: 2010; n=875

Sweden: 2008; n=16271

UK (E&W): 2010/11; n=9589

Norway: 2009; n=632

Sources:

Reitox national reports 2011, taken from surveys, reports or scientific articles.

Download spreadsheet version (.xls)

Country	Amphetamines	Ecstasy	Cocaine
Romania (2010)	0.0	0.4	0.2
Greece (2004)	0.1	0.4	0.2
Poland (2006)	1.3	0.7	0.3
Lithuania (2008)	1.1	1.9	0.3
Hungary (2007)	1.2	1.0	0.4
Czech Republic (2010)	0.8	1.6	0.5
Norway (2009)	0.8	0.8	0.6
Finland (2010)	1.6	1.1	0.6
Latvia (2007)	1.9	2.7	1.0
Portugal (2007)	0.4	0.9	1.2
Austria (2008)	0.9	1.0	1.2
Sweden (2008)	1.5	0.2	1.2
Estonia (2008)	2.5	2.3	1.3
Slovakia (2006)	0.7	2.7	1.3
Bulgaria (2008)	2.1	1.6	1.5
Germany (2009)	1.9	1.0	1.8
France (2010)	0.5	0.4	1.9
Cyprus (2009)	0.7	1.0	2.2
Netherlands (2009)		3.1	2.4
Denmark (2010)	2.0	0.8	2.5
Ireland (2010/11)	0.8	0.9	2.8
Italy (2008)	0.6	1.0	2.9
United Kingdom (E&W) (2010/11)	2.0	3.0	4.2
Spain (2009)	1.4	1.8	4.4

gpsfig17

Demonstration	Reference	Type	Y Axis	X axis	Label	Width (%)	Height (px)	Y plotline	Y min,max values	series Markers
	szrfig1	column,column,line	Quantity (kg)\|Number of seizures$3
	szrfig2	column,column,line	Quantity (kg)\|Number of seizures$3
	gpsfig4a	line	%				500		0,30
	gpsfig1	column	%				500		0,25
	gpsfig2	column,column,point	Contiuation rates %\|LTP all adults$3
	gpsfig18a	distribution	Estimated prevalence (%)						0
	gpsfig18b	distribution	Estimated prevalence (%)						0
	gpsfig20	column	%				600		0,20
	dlofig2	stackedBar	%				600
	dlofig3	line	Index (2005 = 100)			68
	dlofig3$	pie			1 073 752 reports (2010)	30
	dlofig4	line	Index (2005 = 100)			68
	dlofig4$	pie			1 073 752 reports (2010)	30
	dlofig5	line	Index (2005 = 100)			68
	dlofig5$	pie			189 792 reports (2010)	30
	drdfig12a	scatter	Ratio between DRD in 2003 and 2000	Number of DRD in 2000				1
	drdfig12b	scatter	Ratio between DRD in 2009/10 and 2003	Number of DRD in 2003				1
	hsrfig2	stackedColumn	Clients in substitution treatment
	dlofig1	line	Index (2005 = 100)						90,140
	drdfig1	column	Country and total number of DRD				600
	drdfig2	column	Proportion of DRD under the age of 25 (%)				600
	drdfig3	line	Mean age in years
	drdfig4	line	Mean age in years
	drdfig5a	line	Index (1990 = 100)
	drdfig5b	line	Index (1996 = 100)
	drdfig6	line	Index (1990 = 100 %)						80,160
	drdfig7a	column	Mortality rate per million
	drdfig7b	column,point	Rate per million
	drdfig8	line	Index (1985 = 100 %)						50,650
	drdfig9a	line	%						0,70
	drdfig9b	line	%
	drdfig9c	line	%
	drdfig10	column	Mean age in years				500
	drdfig11a	line	Index						0,300
	drdfig11b	line	Index
	drdfig11c	line	Index
	drdfig13a	line	Number of cases
	drdfig13b	line	Number of cases
	eyefig1a	line
	eyefig1b	line
	eyefig1c	line							0,
	eyefig1d	line	%			45	800
	eyefig1d$	line	%			45	800
	gpsfig3	column	%				500
	gpsfig4b	line	%
	gpsfig5	column	%
	gpsfig6	column	%
	gpsfig7	column	%
	gpsfig8a	line	%						0,
	gpsfig8b	line	%						0,
	gpsfig9a	column	%
	gpsfig9b	column	%
	gpsfig10	line	%
	gpsfig11	column,column,point	Continuation rates (%)\| LTP All adults$3
	gpsfig12a	line	%						0,
	gpsfig12b	line	%						0,
	gpsfig13	column,column,point	%
	gpsfig14a	line	%						0,
	gpsfig14b	line	%						0,
	gpsfig15	column	%
	gpsfig16	column,column,point	Continuation rates (%)\|LTP All adults$3						0,
	gpsfig17	column	%
	gpsfig21a	line	%						0,
	gpsfig21b	line	%						0,
	gpsfig22	column,column,point	Continuation rates (%)\| LTP All adults$3
	gpsfig23a	line	%
	gpsfig23b	line	%
	gpsfig23c	line	%
	gpsfig23d	line	%						0,
	gpsfig23e	line	%						0,
	hsrfig4	pie			% of prison population in OST	30
	inffig1a	line	New AIDS cases per million population				700		0,
	inffig1b	line	New AIDS cases per million population				700		0,
	inffig2a	line	Cases per million population						0,
	inffig2b	line	Cases per million population						0,
	inffig2c	line	Cases per million population
	inffig2d	line	Cases per million population
	inffig3a	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	inffig3b	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	inffig3c	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	inffig6a	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	inffig6b	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	inffig6c	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	inffig9a	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	inffig9b	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	pppfig1	line	Index (2005 = 100)
	pppfig2	line	Index (2005 = 100)
	tdifig1a	line	%
	tdifig1b	line
	tdifig2a	pie				30
	tdifig2b	pie				50
	tdifig3a	line	%
	tdifig3b	line
	tdifig7	line	%			60			0,
	tdifig7$	stackedColumn	Numbers			38
	hsrfig1b	percentStackedColumn	%































Distirbuted points with specific markers and colours	inffig6a	distribution	%							National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)